Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $2,546 | $2,923 | $2,802 | $2,671 | $2,567 |
| Gross Profit | $1,438 | $1,641 | $1,567 | $1,427 | $1,379 |
| Operating Income | $411 | $489 | $483 | $338 | $269 |
| Net Income | $3,806 | $4,246 | -$3,628 | -$637 | -$1,844 |
Over the past five years, BIO‐RAD LABORATORIES, INC. has experienced mixed financial performance. Revenue peaked in 2021 at USD 2,922.5 million but subsequently declined to USD 2,566.5 million by 2024—a drop of roughly 12% from its peak. Gross profit showed a similar pattern, rising from USD 1,437.8 million in 2020 to a maximum of about USD 1,640.7 million in 2021 before declining steadily to USD 1,378.9 million in 2024, reflecting potential pressure on production efficiency or rising costs despite relatively stable revenue levels. Operating income also peaked in 2021 (USD 489.4 million) and then fell to USD 269 million by 2024, indicating narrowing margins that may point to increased operating expenses or pricing pressures in the competitive life science and diagnostics market. Notably, net income swung dramatically, with robust profitability in 2020 (USD 3,806.3 million) and 2021 (USD 4,245.9 million) giving way to significant losses in subsequent years – a steep decline to a loss of USD 3,627.5 million in 2022, followed by incremental improvements to a loss of USD 637.3 million in 2023 and again a loss of USD 1,844.2 million in 2024. This >20% year-over-year volatility, particularly the turnaround from profit to a deep loss in 2022, suggests the company may have encountered operational disruptions, increased cost pressures, or market headwinds. Overall, while BIO‐RAD’s core revenue and gross profit trends remain relatively stable, the pronounced fluctuations in net income raise concerns about short-term financial sustainability, implying a need for strategic operational adjustments to restore consistent profitability in a competitive industry.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.